<DOC>
	<DOC>NCT00712725</DOC>
	<brief_summary>The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.</brief_summary>
	<brief_title>MK3207 for Treatment of Acute Migraines (3207-005)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Men and Women from 18 to 65 years of age 1+ year history of migraine that typically last from 4 to 72 hours if untreated Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months Not pregnant or planning to become pregnant in next 6 months Pregnant or breastfeeding, or planning to become pregnant in next 6 months Cannot distinguish migraine attacks from tension type headaches Migraines are mild or resolve without medication in less than 2 hours More than 15 headachedays per month or have taken medication on more than 10 days per month in the last 3 months Basilar type or hemiplegic migraine headaches More than 50 years old when migraines began History of cardiovascular disorder within last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>